32 completed, 6 active not recruiting, 5 terminated, 3 unknown. 41 Phase 2, 13 Phase 1, 4 Phase 3, 1 Phase 4.
Follow Pentostatin: new trials by email Literature Review of Pentostatin trials Research Report on Pentostatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy INCA034176, Best Available Therapy (BAT) - Chronic Graft-versus-host-disease | Phase 3 | Active not recruiting | Incyte Corporation | 9 | 2025-06-04 | 2026-08-25 |
| A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia Anti-Thymocyte Globulin, Biospecimen Collection, Bone Marrow Aspirate - Recurrent Severe Aplastic Anemia, Refractory Severe Aplastic Anemia | Phase 1 | Recruiting | City of Hope Medical Center | 6 | 2024-11-15 | 2026-01-05 |
| A Blood Stem Cell Transplant for Sickle Cell Disease Cyclophosphamide, Pentostatin, Rabbit anti-thymocyte globulin - Sickle Cell Disease, Sickle Cell Disorder | Phase 1 | Active not recruiting | City of Hope Medical Center | 3 | 2019-01-04 | 2026-03-05 |
| Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation e-ATG, Immunosuppression Only Conditioning, Reduced Intensity Conditioning - Lymphoproliferative Disorders, Autoimmune Lymphoproliferative | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 71 | 2018-09-04 | 2026-03-17 |
| A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX) - Graft-versus-host Disease (GVHD) | Phase 3 | Completed | Incyte Corporation | 330 | 2017-06-29 | 2025-08-12 |
| Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease haploidentical stem cell transplant, Sirolimus, Alemtuzumab - Sickle Cell Disease | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 57 | 2017-04-06 | 2026-04-23 |
| Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure Alemtuzumab, Sirolimus, Cyclophosphamide - Sickle Cell Disease, Thalassemia | Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 56 | 2014-04-21 | 2026-08-18 |
| Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia Pentostatin, Cyclophosphamide, Ofatumumab - Chronic Lymphocytic Leukemia | Phase 2 | Completed | Niguarda Hospital | 47 | 2011-09-01 | 2016-12-28 |
| Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma Bendamustine, Pentostatin, Ofatumumab - Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin's Lymphoma | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 10 | 2011-05-25 | 2025-04-29 |
| SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma Pentostatin, Cyclophosphamide, SS1(dsFv)PE38 - lot 073I0809 - Mesothelioma, Adenocarcinoma of Lung | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2011-05-11 | 2019-06-06 |
| Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies Methotrexate, Pentostatin - Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia | Phase 3 | Completed | St. Jude Children's Research Hospital | 6 | 2010-09-01 | 2013-03-21 |
| Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia Pentostatin, Rituximab, Bendamustine - Hairy Cell Leukemia | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 69 | 2010-07-01 | 2026-10-15 |
| Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma MTD of Velcade, Nipent and Rituxan established in Part 1 - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 1 / Phase 2 | Withdrawn | Louisiana State University Health Sciences Center Shreveport | 2010-05-01 | 2020-09-01 | |
| Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Cyclophosphamide, Laboratory Biomarker Analysis, Ofatumumab - Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 82 | 2010-03-01 | 2018-09-18 |
| Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma DCS (docetaxel with cisplatin with TS-1), DCF (docetaxel with cisplatin with 5-FU) - Gastric Cancer | Phase 2 | Completed | Yonsei University | 6 | 2009-09-01 | 2024-12-27 |
| Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease Pentostatin; Cyclophosphamide; Rituximab - Active Chronic Graft Versus Host Disease | Phase 2 | Withdrawn | University of Rochester | 2009-08-01 | 2013-10-16 | |
| Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma bevacizumab, pegfilgrastim, rituximab - Leukemia, Lymphoma | Phase 2 | Completed | Mayo Clinic | 68 | 2009-02-01 | 2017-06-15 |
| Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer cyclosporine, mycophenolate mofetil, pentostatin - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 / Phase 2 | Withdrawn | University of Nebraska | 2008-09-01 | 2023-08-14 | |
| Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma alemtuzumab, rituximab, pentostatin - Leukemia, Lymphoma | Phase 2 | Completed | Mayo Clinic | 41 | 2008-07-01 | 2014-07-01 |
| Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia Cordycepin plus Pentostatin - Refractory TdT-Positive Leukemia | Phase 1 / Phase 2 | Unknown | OncoVista, Inc. | 44 | 2008-06-01 | 2009-01-09 |
Showing 20 of 50. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (22) · Leukemia (18) · Lymphoma (17) · Graft vs Host Disease (12) · Lymphoma, B-Cell, Marginal Zone (7) · Lymphoma, Follicular (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Hodgkin Disease (6) · Lymphoma, Non-Hodgkin (6) · Leukemia, Myeloid, Acute (5) · Myelodysplastic Syndromes (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Lymphoma, Mantle-Cell (4) · Anemia, Sickle Cell (3) · Bronchiolitis Obliterans Syndrome (3)
M.D. Anderson Cancer Center (4) · Mayo Clinic (4) · National Cancer Institute (NCI) (4) · Eastern Cooperative Oncology Group (3) · Memorial Sloan Kettering Cancer Center (3) · National Heart, Lung, and Blood Institute (NHLBI) (3) · City of Hope Medical Center (2) · Incyte Corporation (2) · Ohio State University Comprehensive Cancer Center (2) · University of Nebraska (2) · Alliance for Clinical Trials in Oncology (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Astex Pharmaceuticals, Inc. (1) · Boston Medical Center (1) · East Valley Hematology and Oncology Medical Group (1)
United States (45) · Italy (4) · Austria (2) · Belgium (2) · Czechia (2) · France (2) · Germany (2) · Greece (2) · Netherlands (2) · Norway (2) · Portugal (2) · South Korea (2) · Spain (2) · Sweden (2) · Switzerland (2)
Renier Brentjens, MD, PhD (2) · Tait D. Shanafelt, MD (2) · Agostino Cortelezzi, MD (1) · Alessandro Rambaldi, MD (1) · Andrew D. Zelenetz, MD, PhD (1) · Andrew M Yeager, MD (1) · Anthony D Ho, Ph.D., Prof. (1) · Antonino Mazzone, MD (1) · Armando Santoro, MD (1) · Asha Pillai, MD (1) · Brenda Sandmaier (1) · Clive S. Zent, MD (1) · Courtney F Joseph, M.D. (1) · Craig Hofmeister, MD (1) · Craig Reynolds, MD (1)
PMID 36240296, PMID 42133908, PMID 12663715, PMID 16520464, PMID 17514743, PMID 19443659, PMID 19654407, PMID 19745067, PMID 19925875, PMID 20187101, PMID 20541024, PMID 22383800, PMID 23588536, PMID 24431228, PMID 24723493, PMID 26071480, PMID 26294723, PMID 27570087, PMID 29316837, PMID 33225826, PMID 34260836, PMID 35363318, PMID 40010689, PMID 40472328, PMID 40561385, PMID 41060318, PMID 41871072, PMID 42180389
P30CA015083 (3), U10CA021115 (2), 2016 (1), P01CA078902 (1), P30CA008748 (1), P30CA015704 (1), P30CA033572 (1), P30CA036727 (1), R21CA106177 (1), U01HL069294 (1), U10CA031946 (1)